244 related articles for article (PubMed ID: 15115500)
1. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients.
Vidal D; Alomar A
Clin Exp Dermatol; 2004 May; 29(3):237-9. PubMed ID: 15115500
[TBL] [Abstract][Full Text] [Related]
2. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
4. Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma.
Shulstad RM
Dermatol Nurs; 2009; 21(2):86-7. PubMed ID: 19507375
[TBL] [Abstract][Full Text] [Related]
5. Nonsyndromic multiple basal cell carcinomas successfully treated with imiquimod 5% cream.
Kocabaş E; Ermertcan AT; Bilaç C; Bilaç DB; Temiz P
Cutan Ocul Toxicol; 2010 Dec; 29(4):300-2. PubMed ID: 20684662
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas.
Marks R; Owens M; Walters SA;
Arch Dermatol; 2004 Oct; 140(10):1284-5. PubMed ID: 15492200
[No Abstract] [Full Text] [Related]
7. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
8. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
[TBL] [Abstract][Full Text] [Related]
9. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report.
Micali G; De Pasquale R; Caltabiano R; Impallomeni R; Lacarrubba F
J Dermatolog Treat; 2002 Sep; 13(3):123-7. PubMed ID: 12227875
[TBL] [Abstract][Full Text] [Related]
10. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
Quirk C; Gebauer K; Owens M; Stampone P
Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
[TBL] [Abstract][Full Text] [Related]
11. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
12. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
Drehs MM; Cook-Bolden F; Tanzi EL; Weinberg JM
Dermatol Surg; 2002 May; 28(5):427-9. PubMed ID: 12030878
[TBL] [Abstract][Full Text] [Related]
14. Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
Warshauer E; Warshauer BL
J Drugs Dermatol; 2008 May; 7(5):447-51. PubMed ID: 18505136
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
[TBL] [Abstract][Full Text] [Related]
16. 5% imiquimod cream for the treatment of large superficial basal cell carcinoma.
Shumack S; Gebauer K; Quirk C; Macdonald K; Walters SA; Owens M
Arch Dermatol; 2004 Oct; 140(10):1286-7. PubMed ID: 15492202
[No Abstract] [Full Text] [Related]
17. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
[TBL] [Abstract][Full Text] [Related]
18. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study.
Vun Y; Siller G
Australas J Dermatol; 2006 Aug; 47(3):169-71. PubMed ID: 16866996
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.
Sriprakash K; Godbolt A
Australas J Dermatol; 2009 Aug; 50(3):211-3. PubMed ID: 19659986
[TBL] [Abstract][Full Text] [Related]
20. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.
Wu JK; Oh C; Strutton G; Siller G
Australas J Dermatol; 2006 Feb; 47(1):46-8. PubMed ID: 16405483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
